J&J to build $1bn US CGT manufacturing site in Pennsylvania

Johnson & Johnson (J&J) has chosen Pennsylvania arsenic location to its caller $1bn compartment therapy manufacturing facility, arsenic the Trump medication looks to onshore cause accumulation to the US amid increasing planetary competition.

Once operational, the Montgomery County-based, next-generation accumulation tract volition make much than 500 skilled biomanufacturing roles. The facility’s improvement volition besides unfastened up 4,000 operation positions. The Pennsylvania installation volition beryllium J&J’s eleventh tract wrong the state, which is already location to manufacturing, distribution, probe and office-based sites.

While J&J did not stock further details connected the operation timeline for the tract oregon what it volition beryllium built to produce, the institution presently has 1 compartment therapy, Carvykti (ciltacabtagene autoleucel), connected the market, which became a blockbuster seller for J&J successful FY2025 aft bringing successful $1.9bn successful planetary sales. GlobalData, genitor institution of Pharmaceutical Technology, presently forecasts that Carvykti volition make income of $7.8bn successful 2031.

The Pennsylvania-based installation is 1 of 4 US enlargement initiatives J&J has announced successful caller months – each of which autumn nether its $55bn inaugural to grow its manufacturing beingness connected location soil. Under this scheme, the institution has begun operation connected a $2bn biologics accumulation installation successful Wilson, North Carolina.

Around the clip J&J agreed to a Most Favored Nation (MFN) woody with the White House to debar 100% tariffs connected its branded imports, the institution besides noted that it would conception a cause merchandise manufacturing tract successful North Carolina – though nary further details connected this physique were shared.

J&J’s moves to onshore its manufacturing to the US travel a wider inclination observed crossed the pharma industry, arsenic companies look to align their activities with the Trump administration’s goals. As US pharma manufacturing efforts continue, manufacture experts enactment that newer biotech hubs similar North Carolina and Virginia volition summation prevalence.

While immoderate companies similar J&J treble down connected their compartment therapy operations, this attack is not unanimous crossed pharma and biotech.

For example, Takeda chose to measurement distant from compartment therapy to absorption its attraction connected tiny molecules, biologics and antibody-drug conjugates (ADCs) backmost successful October 2025. In the aforesaid month, Novo Nordisk and Galapagos besides shuttered their units focused connected the modality.

Meanwhile, companies similar Eli Lilly are leaning into the modality, arsenic the pharma elephantine has already signed 2 blockbuster deals involving this cause people successful 2026 – including a $1.1bn cistron therapy-focused woody with Seamless Therapeutics and an successful vivo CAR-T woody worthy up to $2.4bn with Orna Therapeutics.